Actinic Keratosis Market Is Anticipated To Reach US$ 8,070.0 Mn In 2022 And Grow At A CAGR Of 4.7% During The Projected Period (2022-2030)

Actinic Keratosis Market
Actinic Keratosis Market

Actinic keratosis is skin damage brought on by too much sun exposure. A fairly prevalent precursor to skin cancer is actinic keratosis. Actinic Keratosis Market is regarded as a chronic condition, and the majority of patients eventually develop recurring lesions. Squamous cell carcinoma (SCC), a frequent and occasionally aggressive skin cancer, can develop from actinic keratosis, increasing the risk of skin cancer. Squamous cell carcinoma, a cancerous skin tumor that arises from keratinizing cells (keratinocytes) in the epidermis or skin adnexa, has actinic keratosis as an early precursor. The likelihood that actinic keratosis will progress to SCC makes therapy typically advised. Cryotherapy, photodynamic therapy, or topical medications are typically used in the treatment of this illness.

Over the forecast period, the worldwide Actinic Keratosis Market is anticipated to rise due to high treatment efficacy. The actinic keratosis for market is anticipated to increase at a significant rate throughout the projected period due to the high efficacy of treatments available for the condition. For instance, a May 2017 publication in the monthly peer-reviewed medical journal Australian Family Physician indicated that the effectiveness of cryosurgery for the treatment of actinic keratosis ranges from 86% to 99%.

Additionally, a variety of actinic keratosis therapies are offered globally, giving patients a variety of options. This is anticipated to further accelerate the expansion of the global actinic keratosis for market. The negative effects of the medications prescribed to treat actinic keratosis are predicted to hinder the growth of the global Actinic Keratosis Market in the near future. The majority of dermatologists in the U.S. have traditionally preferred cryotherapy for the treatment of actinic keratosis due to more favorable financial reimbursement, whereas dermatologists in Europe have preferred topical prescriptions such as fluorouracil, ingenol mebutate, and others due to the lack of reimbursement for procedures like photodynamic therapy. This is according to data published by Biofrontera AG Investor Presentation in January 2020.

Comments

Popular posts from this blog

Security Robot Market to Reach US$ 11.8 Billion by 2022

Intravenous Fluid Therapy is the Fastest Growing Segment Fueling the Growth of Intravenous Solutions Market

Global Report on LED Driver Market for the Forecast Period 2023-2030